Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
On this week’s episode of “The Readout LOUD,” our STAT colleague Nicholas Florko joins us to explain what it means to be a reporter who writes about the commercial determinants of health. Hint: Florko ...
Duchenne therapy may be evolving from slowing disease to reversing it—with RNA approaches offering the prospect of restoring function. Ongoing research will determine if these advances can deliver ...
A Sarepta Therapeutics gene therapy that failed its confirmatory test has now converted its accelerated FDA approval into a traditional one, expanding use of the treatment to a wider group of Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results